Journal article
The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial
Abstract
BACKGROUND AND OBJECTIVES: Mineralocorticoid receptor antagonism reduces morbidity and mortality in patients with heart failure, but the safety of these drugs in patients receiving dialysis is unclear. This study evaluated whether hyperkalemia and/or hypotension limited the use of eplerenone, a selective mineralocorticoid receptor antagonist, in hemodialysis patients.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a randomized …
Authors
Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ
Journal
Clinical Journal of the American Society of Nephrology, Vol. 10, No. 9, pp. 1602–1608
Publisher
Wolters Kluwer
Publication Date
September 2015
DOI
10.2215/cjn.12371214
ISSN
1555-9041